Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453024 | 0.76 | POLB (0.39) | TSHRTP53RAB9ASMN1; SMN2DAGLA | |
| SCHEMBL23277327 | 0.75 | — | — | |
| SCHEMBL15322198 | 0.74 | CYP2D6 (0.39) | TSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL19347393 | 0.72 | KMT2A (0.39) | TSHRTP53RAB9ASMN1; SMN2POLB | |
| SCHEMBL15322502 | 0.71 | CYP2D6 (0.34) | TSHRSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL19347967 | 0.70 | ALDH1A1 (0.40) | TSHRSMN1; SMN2POLBALDH1A1GAA | |
| SCHEMBL21910791 | 0.69 | PKM (0.39) | TSHRTP53RAB9ASMN1; SMN2POLB | |
| SCHEMBL22455534 | 0.68 | RAB9A (0.48) | TSHRTP53RAB9ASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL28684913 | 0.68 | GRIA4 (0.50) | TSHR | |
| SCHEMBL15017837 | 0.68 | TP53 (0.40) | TRPV1TP53RAB9ASMN1; SMN2DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| EP-3723807-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3723808-B1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H LUNDBECK AS (DK) | 2021-10-20 | — | — | EP | disclosed |
| EP-3558988-B1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2021-07-07 | — | — | EP | disclosed |
| US-11026923-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| US-11026924-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-06-08 | — | — | US | disclosed |
| US-20210023056-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-01-28 | — | — | US | disclosed |
| US-20210015794-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-01-21 | — | — | US | disclosed |
| US-20200385381-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | H. LUNDBECK A/S (DK) | 2020-12-10 | — | — | US | disclosed |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2018-01-04 | — | — | US | disclosed |
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | disclosed |
| US-9045479-B2 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-06-02 | — | — | US | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026924-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | TSHR 2991/4885TRPV1 3391/4885TP53 4642/4885 |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | NTRK1, MUSK, NTRK3 | TSHR 362/4885TRPV1 1045/4885TP53 702/4885 |
| US-20200385381-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES | PDE1B, PDE3B, PDE1A | TSHR 2356/4885TRPV1 3083/4885TP53 4607/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | TSHR 3677/4885TRPV1 3154/4885TP53 3573/4885 |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | PDE1B, PDE3B, PDE1A | TSHR 2356/4885TRPV1 3083/4885TP53 4607/4885 |
| US-11026923-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE3A, PDE5A, PDE12 | TSHR 2941/4885TRPV1 3381/4885TP53 4645/4885 |
| US-20180000786-A1 | 1H-Pyrazolo[4,3-b]pyridines as PDE1 Inhibitors | PDE3A, PDE5A, PDE12 | TSHR 2941/4885TRPV1 3381/4885TP53 4645/4885 |
| US-20210015794-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE12 | TSHR 2991/4885TRPV1 3391/4885TP53 4642/4885 |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | TSHR 3129/4885TRPV1 1924/4885TP53 4682/4885 |
| US-20210023056-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE12 | TSHR 2941/4885TRPV1 3381/4885TP53 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.